[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

World Market for Anti-Infectives Analysed by Kalorama Information

15 Feb 2012 • by Natalie Aster

With combined sales from the top HIV treatment on the market and several other drugs, Gilead Sciences leads the antiviral market, according to healthcare market research publisher Kalorama Information, closely followed by Bristol-Myers Squibb, Roche and Merck.

Led by growth in antivirals, the market for all anti-infectives reached $53 billion in 2011, according to Kalorama Information’s new report « World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)».

Atripla is the company’s newest antiviral product, launched in July 2006, and it’s the leading treatment for HIV. It is a nucleoside analog, part of a highly active antiretroviral therapy (HAART) regimen or “cocktail” that under best conditions can reduce the presence of HIV RNA in the patient’s plasma to undetectable levels, thus prolonging survival. Kalorama estimated the product’s sales to be $3.2 billion in 2011. Truvada, Viread, Hepsera are the company’s other antiviral drugs. However, the report finds this is a highly competitive market and other brands are competing for market leadership.

Report Details:

World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)
Published: February, 2012
Pages: 220
Price: US$ 3.800,00

Bristol-Myers Squibb holds second place in the antiviral drug market, according to Kalorama Information. The company’s Baraclude nucleoside analog has grown from $257 million in sales in 2007 to $1.1 billion today. The company’s other leading antiviral drugs are Sustiva and Reyataz. Roche holds the third market position overall; the company’s key antivirals include Pegasys, Valcyte, and Tamiflu.

GlaxoSmithKline alone accounted for 25% of the antiviral market in 2009, but has since declined due to patent expirations on key products. The company is not inactive, however. In November 2009, GlaxoSmithKline and Pfizer launched ViiV Healthcare, a new company focusing on HIV treatment that combines the strength of both companies’ product and development pipelines in the HIV treatment area. For 2011, the new company accounted for one tenth of the antiviral drug market, according to Kalorama.

Of all the anti-infective drug markets that Kalorama has researched in its report, antivirals presented the most growth and competitive activity. This trend is expected to continue for 2011 with half year sales for key products already showing similar increases. Kalorama’s report, World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals), contains more segment market estimates, estimates for revenues by infection treated, and profiles of key companies in the market.

More information can be found in the report “World Market for Anti-Infectives Analysed by Kalorama Information” by Kalorama Information.

To order the report or ask for sample pages contact [email protected]


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest